Illustrative AI-generated image of a medicine consultation; it does not depict study participants.
New research is drawing attention to nail and hair complaints among people taking GLP-1 medicines. The findings, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, identify a pattern worth investigating, with important limits on what it means.
Researchers compared 575 GLP-1 users with 1,329 people with obesity, type 2 diabetes, or both who had never taken these medicines. Participants came from France, the United States, Brazil and Mexico. Nail detachment was reported by 39% of users versus 9% of nonusers; discoloration by 46% versus 17%.
A companion analysis of the same participants found unusual hair loss in 50% of users versus 34% of nonusers. Reduced hair volume or density was reported by 42% versus 19%. These are separate hair findings, not measures of nail damage.
The numbers do not mean that 39% of people starting a GLP-1 medicine will develop nail detachment. These were cross-sectional surveys: participants described symptoms at one point in time. The studies did not randomly assign treatment or establish which symptoms the medicines caused.
Timing is especially important. Study author Charles Taïeb told Healthline that the nail-detachment association almost vanished when researchers considered only changes beginning after treatment started. He also said the findings had been submitted to dermatology journals and were under review when Healthline reported on October 7. A conference finding should therefore be read as preliminary evidence, rather than a settled conclusion.
About half of users reported nail problems predating treatment. Researchers plan follow-up studies with clinical examinations to clarify timing and causes. The research received institutional support from DUCRAY Laboratories, part of Pierre Fabre. If you notice nail changes, hair shedding or scalp symptoms, discuss them with your prescriber; do not stop prescribed treatment without medical advice.
Sources
- EADV official research announcement (PDF) — primary nail study abstract AS-1799, Piraccini BM et al., EADV 2026; companion scalp study Halioua B et al.
- Author interview and timing clarification — Healthline
- Presenting author’s summary
- Original coverage shared by the reader — The Epoch Times (not accessed; this article was independently researched).
